Abstract
Objective
The aim of this study was to evaluate the recent efficacy and adverse reactions of recombinant human endostatin (Endostar) plus chemotherapy in the treatment of advanced malignancies.
Methods
One hundred and seventeen cases of advanced malignancies were diagnosed and confirmed by histopathological examination, patients were treated with Endostar combined with chemotherapeutic drugs with no cross-resistance. Evaluate the efficacy and adverse reactions after finished two cycles of combination therapy.
Results
All the 117 cases of patients were evaluated according to relevant standards, and there were 12 cases of complete remission (CR), 30 cases of partial remission (PR), 58 cases of stable disease (SD), 17 cases of progressive disease (PD). The response rate (RR) was 35.8%, disease control rate (DCR) was 85.4%.
Conclusion
The protocol of Endostar combined with chemotherapy could improve the quality of life of patients with malignances, it also has the advantage of low toxicity. Considering the time span of the study, the long-term efficacy remains to be observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Qin HF, Gao HJ, et al. Advances in research on recombinant human endostatin (EndostarTM ) in the treatment of non-small cell lung cancer. Mili Med Sci (Chinese), 2011, 35: 553–560.
Hu K, Ge W. Tumor vascular network and micro-environment characteristics. Chin J Microcirc (Chinese), 2010, 20: 44–46.
Cao DD, Ge W, Wang HM, et al. Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review. Chin J Lung Cancer (Chinese), 2011, 14: 404–413.
Xie K, Zhang M, Liang L, et al. Rh-endostatin injection combined with chemotherapy on the advanced malignancies. Chin Clin Oncol (Chinese), 2009, 14: 466–469.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua- tion criteria in solid tumours: revised RECIST guideline (version1.1). Eur J Cancer, 2009, 45: 228–247.
Miller AB, Hoogstraten B, Staqvet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207–214.
Zhou M, Luo YQ, Yao LJ, et al. Gene expression and clinical research in lung cancer α3 (IV). Acta Univ Med Anhui (Chinese), 2012, 47: 48–52.
Chen YX, Qin SK, Liu XF, et al. Clinical study of rh-endostatin combined with chemotherapy for advanced gastric cancer. Chin Clin Oncol (Chinese), 2009, 14: 327–331.
Wang JW, Sun Y, Liu YY, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chinese), 2005, 8: 283–290.
Ni CC, Yu M, Zhang ZH, et al. The role of EGFR and PI3K/AKT signal pathway in non-small cell lung cancer. Acta Univ Med Anhui (Chinese), 2011, 46: 1264–1266.
Liu L, Zhang JZ, Li CH. Study of the impact of CT/CT image fusion radiotherapy on V20 and radiation pneumonitis of non-small cell lung cancer. Chinese-German J Clin Oncol, 2012, 11: 72–75.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ming, P., Ge, W., Liu, L. et al. 117 cases of advanced malignancies treated with recombinant human endostatin plus chemotherapy. Chin. -Ger. J. Clin. Oncol. 12, 61–64 (2013). https://doi.org/10.1007/s10330-012-1114-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-012-1114-6